Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry

Fig. 1

Three-year retention rates of bDMARDs by age group in non-adjusted data. Three-year retention rates of bDMARDs in all patients (a), in patients aged < 65 years (b), in patients aged 65–74 years (c), and in patients aged ≥ 75 years (d). yr = years; no. at risk = number at risk; TNFi = tumor necrosis factor inhibitors; ABA = abatacept; TCZ = tocilizumab

Back to article page